PIRAMAL PHARMA LIMITED

rs,

28th April, 2026 BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 lk, Piramal ~ Pharma Limited Natio

7%

54 YoY % (0)% FY26 FY25 8,869 9,151 YoY % (3)% (in ₹ Crores or as stated) (4)% 7% 17% (16)% CDMO CHG PCH EBITDA EBITDA Margin PAT Before Expectational Item Exceptional

17%

YoY % (0)% FY26 FY25 8,869 9,151 YoY % (3)% (in ₹ Crores or as stated) (4)% 7% 17% (16)% CDMO CHG PCH EBITDA EBITDA Margin PAT Before Expectational Item Exceptional Item1

22%

Before Expectational Item Exceptional Item1 PAT After Expectational Item 1,788 705 274 603 22% NM 154 NM - NM 154 1. During the quarter, the management has recognized an impairment loss o

13%

ent. Accordingly, the carrying amount has been written down in full. 4,915 2,703 1,274 1,135 13% (130) (196) (326) 1,708 755 320 507 18% 167 (176) (9) 5,447 2,633 1,093 1,580 17%

18%

ritten down in full. 4,915 2,703 1,274 1,135 13% (130) (196) (326) 1,708 755 320 507 18% 167 (176) (9) 5,447 2,633 1,093 1,580 17% 91 - 91 (10)% 3% 17% (28)% 9% NM NM

3%

1,708 755 320 507 18% 167 (176) (9) 5,447 2,633 1,093 1,580 17% 91 - 91 (10)% 3% 17% (28)% 9% NM NM Key Highlights • Revenue - Growth was impacted by inventory destocking

9%

0 507 18% 167 (176) (9) 5,447 2,633 1,093 1,580 17% 91 - 91 (10)% 3% 17% (28)% 9% NM NM Key Highlights • Revenue - Growth was impacted by inventory destocking, slower early-st

75%

lthy traction in RFPs and order inflows in H2FY26 driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in FY26) and M&A activity. (Industry Source) - Overseas sites seeing rising demand

30%

n RFPs and order inflows in H2FY26 driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in FY26) and M&A activity. (Industry Source) - Overseas sites seeing rising demand from shifting

47%

n line with CHG business. - Inhalation Anesthesia (IA) o Continue to maintain leadership with 47% market share - up from 45% in Mar’24. (Source:- IQVIA) Initiated Sevoflurane supplies from lower c

45%

- Inhalation Anesthesia (IA) o Continue to maintain leadership with 47% market share - up from 45% in Mar’24. (Source:- IQVIA) Initiated Sevoflurane supplies from lower cost Digwal facility in sele

“• 6 - Power Brands growing at 20%+ CAGR.”

“4,750 5,447 4,915 4,001 2,286 2,449 2,633 2,703 874 985 1,093 1,274 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Stats as per last disclosed data; Piramal Pharma demerged from Piramal Enterprises in 2022 33 Global Footprint with a Diversified Revenue Base tk.”

“Piramal '\ff Pharma Limited 17 Manufacturing and development sites1 100+ Countries with commercial presence ~500 CDMO customers 6,000+ CHG customers (Hospitals) Total FY26 Revenue by Geography Total FY26 Revenue by Segments Others 11% North America 40% Piramal Consumer Healthcare 14% ₹ 8,869 Cr Revenue India 23% Japan 5% 1.”

“Lumigan Glaucoma Brand Segment ► ► BRIMONIDINE TARTRATE EYE DROPS IP0.15% Alphap,{p) -~ Jl(P) Combigan Glaucoma Refresh Tears Dry Eyes Alphagan Glaucoma Pred Forte Eye Inflammation 5 Performance Highlights FY26 a Transitional Year, Expect Return to Growth in FY27 1k.”

“Piramal ~ Pharma Limited ' FY26 was a transitional year, shaped by external disruptions and certain business- specific factors.”

“Nandini Piramal, Chairperson Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT.”

“7 Performance Highlights for Q4 and FY26 1k.”

“Piramal ~ Pharma Limited Revenue from Operations EBITDA & EBITDA Margin Performance Highlights (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin 0% DD 22% 18% 2,754 2,752 603 507 Q4FY25 Q4FY26 Q4FY25 Q4FY26 [ o (3)% l DD 17% 13% 9,151 8,869 1,580 1,135 FY25 FY26 FY25 FY26  Revenue - Ended FY26 on a strong note with healthy double-digit revenue growth in Q4, adjusted for destocking in one large on-patent molecule.”

“ Capex - US$94Mn invested in FY26 across growth and maintenance projects.”

“ Net Debt - No increase compared to FY25.”

For Investor Queries

2

The dial-in details for the call are as under

1

About Piramal Pharma Limited

1

For Media Queries

1

Lacto Calamine OMD Sunscreen Mcanvas Campaign

1

The dial-in details for the call are as under

Event Location & Time India – 09:30 AM IST Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) 1 800 120 1221 (Toll free number) Toll free number 18667462133 Toll free number 08081011573 Toll free number 8001012045 Toll free number 800964448 USA – 12:00 AM (Eastern Time – New York) UK – 05:00 AM (London Time) Singapore – 12:00 PM (Singapore Time) Hong Kong – 12:00 PM (Hong Kong Time) Please use this link for prior registration to reduce wait time at the time of joining the call –Click here Conference call on 29th April 2026 Express Join with Diamond Pass™

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn 1. Includes one facility via PPL’s m

For Media Queries

Madiha Vahid Lead – Branding & Communications madiha.vahid@piramal.com Madhusudan Dalmia Investor Relations madhusudan.dalmia@piramal.com Q4FY26 Results April 2026 Disclaimer tk. Piramal '\ff Pharma Limited This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continu

Lacto Calamine OMD Sunscreen Mcanvas Campaign

Awarded for Most Engaging Mobile Creative and Location-Based Targeting. 131 131 125 148 FY23 FY24 FY25 FY26 Presence Across Platforms Integrated Media Approach: Optimizing digital spends over conventional media ■ Recognition at e4m Health & Wellness Marketing Awards 2025: Won Best Regional Campaign and Best Use of Celebrity/Influencer in the OTC Health Heroes category. MarTech+ Awards 25 – WinnerUse of MarTech for Location-Based Marketing: Lacto Calamine Sunscreen Mcanvas Campaign. Social Media Influencers Television Advertisements Regional Branding Digital Marketing 28 …Driving Growth in Power Brands… ~ Pl1"c1m11I Stay summer proofed ~ i-activ® Period Panty New-age period solutions Piramal Pharma Limited (In ₹ Cr) Strong Growth in our Power Brands [o 22% CAGR Q = ®OO Period Panty Sanitary Pads · FLUFFY SOFT PANTS consumercare@plramal.com t t~on~ to f f lU f f l f fmx ty ,2025amangooa - - - , lrnogeoreror~PIKP<Monly ~ ® gives quick and long lasting relief from acidity OILY SKINCARE Exp

For Investor Queries

Gagan Borana Investor Relations and Enterprise Risk Management Email: gagan.borana@piramal.com Madhusudan Dalmia Investor Relations Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited www.piramalpharma.com Complex Hospital Generics www.piramalcriticalcare.com CDMO www.piramalpharmasolutions.com